Physician profile
Thomas Schnur
NPI 1205827086
$1,736.90
in general payments reported to CMS, 2019-2025
20 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $115 · 2021: $244 · 2022: $324 · 2023: $279 · 2024: $334 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791 · Education: $22.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.25 |
| Education | $22.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $322.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $236.13 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $212.83 | 2019-2025 | |
| Cranial Technologies, INC | $167.32 | 2019-2025 | Doc Band |
| Kaleo, INC. | $148.56 | 2019-2023 | Auvi-Q |
| Tris Pharma INC | $126.67 | 2019-2024 | Dyanavel Xr |
| Glaxosmithkline, LLC. | $101.95 | 2021-2025 | Bexsero, Rotarix |
| Alk-Abello, INC | $70.37 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Ironshore Pharmaceuticals INC. | $57.96 | 2019-2024 | Jornay Pm |
| Seqirus USA INC | $52.21 | 2022-2024 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $43.67 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $38.58 | 2024 | Qelbree |
| Phadia US INC. | $33.03 | 2019-2021 | |
| Neurelis, INC. | $25.61 | 2022 | |
| Otto Bock Healthcare LP | $22.45 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20.05 | 2023 | Flumist Quadrivalent |
| Aquestive Therapeutics, INC. | $18.21 | 2024 | |
| Neurocrine Biosciences, INC. | $14.18 | 2024 | |
| Corium, LLC | $14.11 | 2022 | |
| Genentech USA, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Schnur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.